Finding the needle in the haystack: why high-throughput screening is good for your health

por Aherne, G Wynne, McDonald, Edward, Workman, Paul
Publicado 2002

Aminopyrazine Inhibitors Binding to an Unusual Inactive Conformation of the Mitotic Kinase Nek2: SAR and Structural Characterization

por Whelligan, Daniel K., Solanki, Savade, Taylor, Dawn, Thomson, Douglas W., Cheung, Kwai-Ming J., Boxall, Kathy, Mas-Droux, Corine, Barillari, Caterina, Burns, Samantha, Grummitt, Charles G., Collins, Ian, van Montfort, Rob L. M., Aherne, G. Wynne, Bayliss, Richard, Hoelder, Swen
Publicado 2010

Mechanism-Based Screen for G1/S Checkpoint Activators Identifies a Selective Activator of EIF2AK3/PERK Signalling

por Stockwell, Simon R., Platt, Georgina, Barrie, S. Elaine, Zoumpoulidou, Georgia, te Poele, Robert H., Aherne, G. Wynne, Wilson, Stuart C., Sheldrake, Peter, McDonald, Edward, Venet, Mathilde, Soudy, Christelle, Elustondo, Frédéric, Rigoreau, Laurent, Blagg, Julian, Workman, Paul, Garrett, Michelle D., Mittnacht, Sibylle
Publicado 2012

Discovery of 4-Amino-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamides As Selective, Orally Active Inhibitors of Protein Kinase B (Akt)

por McHardy, Tatiana, Caldwell, John J., Cheung, Kwai-Ming, Hunter, Lisa J., Taylor, Kevin, Rowlands, Martin, Ruddle, Ruth, Henley, Alan, de Haven Brandon, Alexis, Valenti, Melanie, Davies, Thomas G., Fazal, Lynsey, Seavers, Lisa, Raynaud, Florence I., Eccles, Suzanne A., Aherne, G. Wynne, Garrett, Michelle D., Collins, Ian
Publicado 2010

Discovery of 3-Alkoxyamino-5-(pyridin-2-ylamino)pyrazine-2-carbonitriles as Selective, Orally Bioavailable CHK1 Inhibitors

por Lainchbury, Michael, Matthews, Thomas P., McHardy, Tatiana, Boxall, Kathy J., Walton, Michael I., Eve, Paul D., Hayes, Angela, Valenti, Melanie R., de Haven Brandon, Alexis K., Box, Gary, Aherne, G. Wynne, Reader, John C., Raynaud, Florence I., Eccles, Suzanne A., Garrett, Michelle D., Collins, Ian
Publicado 2012

Fragment-Based Screening Maps Inhibitor Interactions in the ATP-Binding Site of Checkpoint Kinase 2

por Silva-Santisteban, M. Cris, Westwood, Isaac M., Boxall, Kathy, Brown, Nathan, Peacock, Sam, McAndrew, Craig, Barrie, Elaine, Richards, Meirion, Mirza, Amin, Oliver, Antony W., Burke, Rosemary, Hoelder, Swen, Jones, Keith, Aherne, G. Wynne, Blagg, Julian, Collins, Ian, Garrett, Michelle D., van Montfort, Rob L. M.
Publicado 2013

The discovery of potent ribosomal S6 kinase inhibitors by high-throughput screening and structure-guided drug design

por Couty, Sylvain, Westwood, Isaac M., Kalusa, Andrew, Cano, Celine, Travers, Jon, Boxall, Kathy, Chow, Chiau Ling, Burns, Sam, Schmitt, Jessica, Pickard, Lisa, Barillari, Caterina, McAndrew, P. Craig, Clarke, Paul A., Linardopoulos, Spiros, Griffin, Roger J., Aherne, G. Wynne, Raynaud, Florence I., Workman, Paul, Jones, Keith, van Montfort, Rob L.M.
Publicado 2013

The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eμ-MYC driven B-cell lymphoma

por Walton, Mike I., Eve, Paul D., Hayes, Angela, Henley, Alan T., Valenti, Melanie R., De Haven Brandon, Alexis K., Box, Gary, Boxall, Kathy J., Tall, Matthew, Swales, Karen, Matthews, Thomas P., McHardy, Tatiana, Lainchbury, Michael, Osborne, James, Hunter, Jill E., Perkins, Neil D., Aherne, G. Wynne, Reader, John C., Raynaud, Florence I., Eccles, Suzanne A., Collins, Ian, Garrett, Michelle D.
Publicado 2015

Structure-Guided Evolution of Potent and Selective CHK1 Inhibitors through Scaffold Morphing

por Reader, John C., Matthews, Thomas P., Klair, Suki, Cheung, Kwai-Ming J., Scanlon, Jane, Proisy, Nicolas, Addison, Glynn, Ellard, John, Piton, Nelly, Taylor, Suzanne, Cherry, Michael, Fisher, Martin, Boxall, Kathy, Burns, Samantha, Walton, Michael I., Westwood, Isaac M., Hayes, Angela, Eve, Paul, Valenti, Melanie, de Haven Brandon, Alexis, Box, Gary, van Montfort, Rob L. M., Williams, David H., Aherne, G. Wynne, Raynaud, Florence I., Eccles, Suzanne A., Garrett, Michelle D., Collins, Ian
Publicado 2011